FWD 2 Commission E: Fixed Combinations of Senna leaf, Peppermint oil, and Caraway oil

  The Commission E Monographs

Fixed Combinations of Senna leaf, Peppermint oil, and Caraway oil


Published January 27, 1991; Replaced November 25, 1993

Name of Drug

Fixed combinations of senna leaf, peppermint oil, and caraway oil.  

Composition of Drug

Fixed combinations consisting of:

Senna leaf, corresponding to monograph B.  Anz. 133 of July 21, 1993;
Peppermint oil corresponding to monograph B.  Anz. 50 of March 13, 1986;
Caraway oil corresponding to monograph in the B.  Anz .  22a of February 1, 1990;

as well as their preparations in effective dosage.  

Pharmacological Properties, Pharmacokinetics, Toxicology

1,8-dihydroxy-anthracene derivatives have a laxative effect.  This laxative effect is based on the sennosides, i.e., on their active metabolite in the colon, rheinanthrone.  The effect is primarily caused by the influence on the motility of the colon as an inhibition of stationary and stimulation of propulsive contractions.  This results in an accelerated intestinal passage and, because of the contact time, a reduction in liquid absorption.  In addition, stimulation of the active chloride secretion increases the water and electrolyte content.  

An antispasmodic action is documented for preparations of peppermint oil and caraway oil.  

The effect of the combination is additive-synergistic.  

Pharmacological studies concerning the effectiveness of the fixed combination are not available.  

Clinical Data

Uses

Constipation, especially with spastic-like discomforts.  

Contraindications

Intestinal obstructions, acutely inflamed intestinal diseases, e.g., Crohn's disease, ulcerative colitis, appendicitis, abdominal pain of unknown origin.  Children under 12 years of age.  In case of gallstones, to be used only after consultation with a physician.  

Side Effects

In single incidents, spastic gastrointestinal discomforts.  In these cases, a dosage reduction is required.  

Chronic use/abuse:

  • loss of electrolytes, especially loss of potassium, albuminuria and hematuria, pigment implantation into the intestinal mucosa ( pseudomelanosis coli ), which is harmless and usually reverses upon discontinuation of the drug.  Potassium deficiency can lead to disorders of heart function and muscular weakness, especially with concurrent use of cardiac glycosides, diuretics and corticoadrenal steroids.  

Special Caution for Use

Stimulating laxatives must not be used over an extended period of time (1 - 2 weeks) without medical advice.  

Use During Pregnancy and Lactation

Because of insufficient toxicological investigations, this drug should not be used during pregnancy and lactation.  

Interactions with Other Drugs

By chronic use/abuse, due to loss in potassium, an increase in effectiveness of cardiac glycosides and an effect on antiarrhythmic drugs is possible.  Potassium deficiency can be aggravated by simultaneous administration of the fixed combination and thiazide diuretics, corticoadrenal steroids, or licorice root.  

Dosage

Unless otherwise prescribed:

Senna leaf must be contained in the amount specified in the monograph.  The essential oils must be present at concentrations of 50 - 70 percent of the daily dosage specified in the respective individual monographs.  

A deviating dosage of the essential oils must be specifically determined for each preparation.  

The individually correct dosage is the smallest dosage necessary to maintain a soft stool.  

Mode of Administration

Liquid and solid preparations for oral use.  

Note:A single administration should be less than the common daily dosage.  

Overdosage

Actions influencing electrolyte and water balance.  

Special Warnings

Usage of a stimulating laxative for longer than the recommended short-term application can cause an increase in intestinal sluggishness.  The preparation should be used only if no effects can be obtained through change of diet or usage of bulk-forming products.  

Effects on Operators of Vehicles and Machinery

None known.